BRPI0507002A - conjugados veìculos de grelina - Google Patents

conjugados veìculos de grelina

Info

Publication number
BRPI0507002A
BRPI0507002A BRPI0507002-3A BRPI0507002A BRPI0507002A BR PI0507002 A BRPI0507002 A BR PI0507002A BR PI0507002 A BRPI0507002 A BR PI0507002A BR PI0507002 A BRPI0507002 A BR PI0507002A
Authority
BR
Brazil
Prior art keywords
vlp
modified
provides
immune responses
producing
Prior art date
Application number
BRPI0507002-3A
Other languages
English (en)
Inventor
Martin F Bachmann
Alma Fulurija
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of BRPI0507002A publication Critical patent/BRPI0507002A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

CONJUGADOS VEìCULOS DE GRELINA . A presente invenção aos campos da biologia melecular, virologia, imunologia e medicina. A invenção fornece uma partícula tipo vírus modificada (VLP) compreendendo uma VLP e peptídeos particulares derivados de grelina igados a ela. A invenção da mesma fornece um precessos para produzir a VLP modificada. As VLPs modificadas da invenção são úteis na produção de vacinas para o tratamento de obsidade e outra doença associada com absorção de alimento aumentada ou peso corporal aumentado e para eficientemente induzir respostas imunes, em particular, respostas de nticorpo. Além disso, as composições da invenção são particulamente úteis para eficientemente induzir respostas imunes alto-específicas dentro do contexto indicado.
BRPI0507002-3A 2004-01-20 2005-01-19 conjugados veìculos de grelina BRPI0507002A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53723004P 2004-01-20 2004-01-20
PCT/EP2005/000497 WO2005068639A2 (en) 2004-01-20 2005-01-19 Particle-induced ghrelin immune response

Publications (1)

Publication Number Publication Date
BRPI0507002A true BRPI0507002A (pt) 2007-06-05

Family

ID=34794443

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507002-3A BRPI0507002A (pt) 2004-01-20 2005-01-19 conjugados veìculos de grelina

Country Status (12)

Country Link
US (1) US20050191317A1 (pt)
EP (1) EP1706152A2 (pt)
JP (1) JP2007518762A (pt)
KR (1) KR20060128924A (pt)
CN (1) CN1905903A (pt)
AU (1) AU2005205181A1 (pt)
BR (1) BRPI0507002A (pt)
CA (1) CA2553594A1 (pt)
IL (1) IL176918A0 (pt)
RU (1) RU2006130006A (pt)
WO (1) WO2005068639A2 (pt)
ZA (1) ZA200604663B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037787A2 (en) 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
WO2006045796A2 (en) * 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
AU2006298767B2 (en) * 2005-09-28 2013-01-10 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
JP5186678B2 (ja) * 2005-10-13 2013-04-17 財団法人ヒューマンサイエンス振興財団 経皮抗原投与のための抗原キット
EA200970166A1 (ru) * 2006-08-01 2009-06-30 Дзе Скриппс Рисерч Инститьют Вакцины и способы для регуляции ожирения
DK2451839T3 (da) * 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
AU2010313282A1 (en) 2009-10-30 2012-05-24 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
HK1200849A1 (en) 2011-12-22 2015-08-14 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10273285B2 (en) 2014-06-18 2019-04-30 Morphosys Ag Fusion proteins and uses thereof
US10526376B2 (en) 2015-01-15 2020-01-07 University Of Copenhagen Virus-like particle with efficient epitope display
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
DK3368068T3 (da) 2015-10-30 2021-02-22 Univ Copenhagen Viruslignende partikler med effektiv epitopdisplay
WO2017170494A1 (ja) * 2016-03-29 2017-10-05 国立大学法人東京大学 抗肥満ワクチン

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4918166A (en) * 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2087997T3 (es) * 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
JPH08505625A (ja) * 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
WO1994017813A1 (en) * 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5770380A (en) * 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
US6380158B1 (en) * 1997-03-24 2002-04-30 Zymogenetics, Inc. Motilin homologs
US6627729B1 (en) * 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
US6291653B1 (en) * 1997-03-24 2001-09-18 Zymogenetics, Inc. Antibodies to motilin homologs
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
NZ506245A (en) * 1998-02-12 2003-08-29 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
AU770802B2 (en) * 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
US6380364B1 (en) * 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
CN1193791C (zh) * 1998-11-30 2005-03-23 希托斯生物技术股份公司 抗原的有序分子呈递,制备及使用的方法
AU770225B2 (en) * 1998-12-04 2004-02-19 Biogen Idec Ma Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
CN101693736B (zh) * 1999-07-23 2020-09-11 寒川贤治 新的肽
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2411667A1 (en) * 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2462857C (en) * 2001-10-05 2012-01-24 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
KR20050044314A (ko) * 2001-11-07 2005-05-12 사이토스 바이오테크놀로지 아게 뼈 질환 치료용 항원 어레이
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
WO2005016951A2 (en) * 2003-06-04 2005-02-24 Eli Lilly And Company Anti-ghrelin fab antibodies

Also Published As

Publication number Publication date
EP1706152A2 (en) 2006-10-04
CN1905903A (zh) 2007-01-31
JP2007518762A (ja) 2007-07-12
WO2005068639A2 (en) 2005-07-28
ZA200604663B (en) 2008-02-27
US20050191317A1 (en) 2005-09-01
WO2005068639A3 (en) 2006-02-02
AU2005205181A1 (en) 2005-07-28
CA2553594A1 (en) 2005-07-28
IL176918A0 (en) 2006-12-10
KR20060128924A (ko) 2006-12-14
RU2006130006A (ru) 2008-02-27

Similar Documents

Publication Publication Date Title
BRPI0511751A (pt) usos médicos de conjugados veìculos de peptìdeos de tnf não-humano
BRPI0507002A (pt) conjugados veìculos de grelina
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
BRPI0516775A (pt) ensaios de polipeptìdeo de antìgeno de inibidor gástrico (gip) e seus usos
BRPI0707779B8 (pt) antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
BRPI0518761A2 (pt) fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
CY1119941T1 (el) Σταθερα και διαλυτα αντισωματα
NO20083793L (no) Antistoffer mot amyloid-beta peptid
BRPI0408623A (pt) conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a
DE60329106D1 (de) Ghrelin-träger-konjugate
IN2014CN03936A (pt)
WO2006097530A3 (en) Cat allergen fusion proteins and uses thereof
WO2006037787A3 (en) Vlp-antigen conjugates and their uses as vaccines
BR112014017384A2 (pt) ácido nucleico que compreende ou codifica para uma estrutura em haste laçada de histona e uma sequência poli (a) ou um sinal de poliadenilação para aumentar a expressão de um antigênio de tumor codificado
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
BR112015021921A2 (pt) Anticorpos biespecíficos tetravalente
BR112014006376A2 (pt) terapia baseada em proteínas e diagnóstico de patologia mediada por tau em doença de alzheimer
WO2009035494A3 (en) Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
BRPI0519026A2 (pt) arranjos de antÍgeno de il-15 e usos dos mesmos
BRPI1014718A2 (pt) polipeptídeo do papiloma vírus humano, capsômero, partícula tipo vírus, composição imunogência, molécula de ácido nucléico, e, métodos para produzir o polipeptídeo, e, para preparar uma composição imunogênica
MX2010006610A (es) Conjugados de factor de crecimiento de nervios y usos de los mismos.
BR112015032713A2 (pt) composto; composição terapêutica; composição farmacêutica; método para tratar o câncer em um paciente em necessidade; e método para induzir anticorpos em um animal ou um humano para a finalidade de criar anticorpos monoclonais para usos terapêuticos ou diagnósticos
BR0213950A (pt) Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
BR0213941A (pt) Arranjos de antìgeno para o tratamento de doença óssea

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 39/00 (2006.01), A61K 47